# Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis

> **NCT05520944** · — · UNKNOWN · sponsor: **Dr. Ferrer BioPharma** · enrollment: 1000 (estimated)

## Conditions studied

- COVID-19
- COVID-19 Pandemic
- COVID-19 Respiratory Infection
- SARS CoV 2 Infection
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **DRUG:** ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray

## Key facts

- **NCT ID:** NCT05520944
- **Lead sponsor:** Dr. Ferrer BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-26
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-10-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2022-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05520944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05520944, "Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05520944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*